Regulation & Compliance

W. R. Berkley's appointment of Kirk Parker isn't just a leadership shuffle; it's a calculated move to master the complex Pacific Northwest market.

Timeero's new Auto Clock-In/Out feature uses geofencing to eliminate missed punches for field teams, tackling a costly source of payroll and compliance issues.

As digital fraud grows, one company's rise to 'Leader' status, fueled entirely by user reviews, reveals what businesses truly need to secure the system.

Insurers bleed cash on flawed customer acquisition. A new AI platform from ZVOX claims to stop the waste by matching every lead with the perfect outreach.

Millions suffer from chronic sciatica with few good options. A small biotech is betting on a novel, non-opioid drug to fix the problem, not just mask it.

A major financial outlook warns that geopolitical fragmentation, stubborn inflation, and a new AI arms race are creating a new reality for investors.

Polish biotech firm Urteste S.A. enrolls its first patient in a pivotal trial for a non-invasive pancreatic cancer test, a milestone in the global race for early diagnosis.

MAIA Biotechnology isn't just opening a new trial site; it's accelerating its assault on a $70B market with a drug showing remarkable early results.

With OpenAI exec Adena Hefets on its board, Entrata isn't just hiring a director; it's signaling a radical shift toward an autonomous future for housing.

Lattice unveils new tools to measure AI's qualitative impact on performance, challenging the industry to move beyond simple usage metrics and prove real ROI.

As businesses rush to advertise on ChatGPT, a critical question emerges: does it work? CallRail's new integration aims to answer that, giving SMBs the tools to measure ROI and compete in the new AI-driven landscape.

The viral foldable home company BOXABL has secured its Nasdaq listing via a SPAC merger. But with a massive valuation and minimal cash from the deal, can it deliver?

With $100M in contracts just five months post-launch, Dapple’s funding isn't just capital—it's a powerful market signal for a new 'fourth option' in AI.

Centro and Sun Life's new API link isn't just a tech update. It’s a signal of a massive shift in a legacy industry, replacing manual processes with speed.

A new US-UK partnership bets on 'agentic AI' to unlock data trapped in public sector systems. Is this the key to modernization or another layer of complexity?

A new deal brings a breakthrough blood cancer therapy, Zemcelpro®, closer to Canada. But for patients with few options, the 2028 timeline is a stark reminder of the gap between innovation and access.

Autonomous AI agents are multiplying in corporate networks, unseen and ungoverned. A new security category, 'AI Agent Governance,' aims to stop a crisis.

As new drugs outpace manufacturing capacity, a French giant bets on local production in China to build the supply chains of tomorrow's therapies.

Guangzhou's top arbitration court opens a Singapore office, a strategic move to serve the Belt and Road and reshape Asia's dispute resolution landscape.

Sylmar Group's acquisition of Tower Water is more than M&A; it's a masterclass in building a resilient enterprise in a critical, regulated sector.